Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. - Wikidata - awgldk - TriplyDB

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q53979216

about

Practical management of classical myeloproliferative disorder patients: a clinician's guide Ruxolitinib: a new treatment option for myelofibrosis.Safety considerations when treating myelofibrosis.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Choosing between stem cell therapy and drugs in myelofibrosis.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.Therapeutic approaches in myelofibrosis.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors Myelofibrosis: an update on current pharmacotherapy and future directions.Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies Pacritinib: a new agent for the management of myelofibrosis?How I treat splenomegaly in myelofibrosis.Treatment of Myelofibrosis: Old and New Strategies.Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.Guideline for the diagnosis and management of myelofibrosis.Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.

P2860

Q28200207-2ABD2E98-03E3-41E8-9AAE-4C7D194B0435 Q33405241-5C685D5E-5986-4545-9EB9-AF89C718AF28 Q33432285-4F3BA99E-B328-4712-AF73-BD9F36CCECC1 Q34302770-DD16BCF5-17FE-4647-BF9C-703271A2D5C2 Q34734491-6794E14B-A09F-41E8-BD98-A1FB52D8E29C Q36001930-7F7C6AFF-A5C8-4662-8B29-845725926D54 Q37163590-C864CC4D-B7FB-4C27-AB74-6ACE6035A3B0 Q37529843-37D651B8-DD13-4D78-AC58-5E15A81D0592 Q37860336-B4BF4119-207E-443C-BBDE-EE8159B2A1A0 Q37877727-0A40A2BE-653F-444B-B7C5-249123056694 Q37968531-F9974F91-A254-40C3-A9A2-63DAD601BC66 Q38031262-2B2320EF-7CEF-49A8-942C-F08896530BF4 Q38091447-739E9948-8090-4B60-BA28-C67056DE069E Q38193610-9866533A-5D20-45D1-AB35-929E0933B682 Q38590232-9019E824-D6A0-4812-A06D-054560916D77 Q39244371-838569A3-2DB5-4DEC-B065-D7E29C1C2B53 Q39349869-79D36875-E271-421C-A2E6-FBEC6921E5A2 Q39612979-16F474AA-FDAC-43E5-9735-447E74828B96 Q42201127-55A8E943-9020-4014-B32B-2306F58AF039 Q50495964-7AB6E17C-3C15-420C-BBE3-21F89CC3715A Q50712240-5D6EA3B1-2F8B-4620-BAAF-8AC59BC7CE2E

P2860

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q53979216

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@en

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@nl

type

label

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@en

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@nl

prefLabel

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@en

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@nl

P1433

Q53979216-874EC36F-7192-46F2-A0EA-4A788A291376

P1476

Q53979216-E591E045-7967-4788-B48B-8B0E2F8868B3

P2093

Q53979216-2DCB79D7-CFA7-4149-A356-8D29B67D91A8

Q53979216-3F198D44-1EB3-46A2-8D02-ED0B86E17EBD

Q53979216-7F92F09F-FD5B-466C-801C-D580D599DAF6

Q53979216-A5704DC4-B2E1-44F7-84AB-E4625A168546

Q53979216-B8F27374-8DEC-436F-9A69-B02D5112F249

Q53979216-B9257B7B-5D91-47F3-8AA3-681DA0F7725E

Q53979216-EAFA826B-7329-4062-8B7F-1B23A5F03052

Q53979216-F03AFC25-5E50-4786-B1D6-24097E320873

Q53979216-F95F9F07-36A5-4A87-B5D9-44498F3D1823

P2860

Q53979216-4B684ECE-C74C-4507-97D6-C031C76770E1

Q53979216-7F2D39DF-A457-44BC-A9B5-585F3DDC570A

Q53979216-B434720F-5CE3-4F39-99E0-0A5CFE0DC11D

Q53979216-EC6A7312-275F-40C6-8D84-E92C21FD046A

Q53979216-F9384012-B37F-4F4B-B8F7-8154A354711E

P304

Q53979216-013200D9-D8DB-4C37-8818-D42B1E44F5A3

P31

Q53979216-99D2310F-AD88-46AD-9640-77311E5AB0E6

P356

Q53979216-AB1942D6-B3AA-4C0A-B677-553CEF208E4E

P407

Q53979216-7D9D88A8-8F2D-4F3E-A5CC-EE0E83086B5D

P433

Q53979216-25D9D620-372F-497B-AD92-831C16CE77BF

P478

Q53979216-88B29905-134B-4DD4-A901-0353AC511BC1

P50

Q53979216-93AA7841-B84C-48D3-BCB9-69D2172939C0

P577

Q53979216-A533D54B-C188-4A1B-9363-FF09502911CD

P5875

Q53979216-33E0DB3D-6B7E-4BF9-BA5F-EA3F76B6EAC8

P698

Q53979216-EEFE27E7-4263-4DE0-8D90-6C1E09646DA3

P356

J.0007-1048.2001.03331.X

P1433

British Journal of Haematology

P1476

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

@en

P2093

Aloe Spiriti MA

http://www.w3.org/2001/XMLSchema#string

Breccia M

http://www.w3.org/2001/XMLSchema#string

Latagliata R

http://www.w3.org/2001/XMLSchema#string

Mandelli F

http://www.w3.org/2001/XMLSchema#string

Montefusco E

http://www.w3.org/2001/XMLSchema#string

Pescarmona E

http://www.w3.org/2001/XMLSchema#string

Petti MC

http://www.w3.org/2001/XMLSchema#string

Spadea A

http://www.w3.org/2001/XMLSchema#string

Spadea T

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.

Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

Idiopathic myelofibrosis--an update with particular reference to clinical aspects and prognosis.

Agnogenic myeloid metaplasia.

P304

576-581

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.0007-1048.2001.03331.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Avvisati

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11512577

http://www.w3.org/2001/XMLSchema#string

P698

11849213

http://www.w3.org/2001/XMLSchema#string